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Background and purpose   Markers of coagulation and fibrinoly-
sis, such as soluble fibrin (SF), D-dimer, and plasminogen activa-
tor inhibitor 1 (PAI-1), have been developed in order to determine 
thrombotic tendency. We investigated whether these markers 
could be used to diagnose venous thromboembolism (VTE) in the 
early phase after primary total hip arthroplasty (THA).
Methods   This prospective study involved 2 groups: an inter-
mittent pneumatic compression (IPC) group (67 patients who 
underwent IPC only as prophylaxis for VTE) and a fondaparinux 
(FPX) group (103 patients who received IPC and FPX postopera-
tively). Plasma levels of SF and PAI-1 were measured on post-
operative day 1. To diagnose postoperative VTE, multi-detector 
row computed tomography (MDCT) and duplex ultrasonography 
(US) were performed on postoperative day 7. 
Results   VTE was detected postoperatively in 17 cases in the 
IPC group (25%) and in 8 cases in the FPX group (6%). In the 
IPC group, plasma levels of SF and PAI-1 were higher in patients 
with VTE (p < 0.01) than in those without VTE. On the other 
hand, in the FPX group there were no differences in the levels 
of SF or PAI-1 measured before administration of FPX on post-
operative day 1. The diagnostic criterion of an increase in SF or 
PAI-1 above the cutoff level (19.8 µg/mL and 53.5 ng/mL, respec-
tively) provided a sensitivity of 100% and a specificity of 67% in 
the IPC group. In addition, when this criterion was applied to 
FPX patients, 7 of the 8 patients with VTE met the criterion, and 
there was a negative agreement rate of 48/49. 
Interpretation   Screening using the cutoff levels of SF and 
PAI-1 may be useful and shows high sensitivity in predicting post-
operative VTE in the early phase after THA. 

 
Randomized clinical trials have shown that the rate of deep 
vein thrombosis (DVT) after total hip arthroplasty (THA) in 
patients who do not receive thromboprophylaxis is 42–57% 
(Geerts et al. 2008). The American College of Chest Physi-
cians (ACCP) recommends routine chemoprophylaxis using 
anticoagulant drugs after total joint arthroplasty of the hip or 
knee (Geerts et al. 2008). However, chemoprophylaxis gener-
ally involves the threat of postoperative bleeding, which must 
be balanced against the risk of thrombotic events.
In Japan, the frequency of postoperative venous thrombo-
embolism (VTE) after THA when no anticoagulant prophy-
laxis is employed is 23–42% (Fujita et al. 2000, Fuji et al. 
2008). The same emphasis has been put on VTE prophylaxis 
as in western countries since the first Japanese guidelines for 
VTE prophylaxis were prepared in 2004 (The first edition 
guidelines for prevention of venous thromboembolism, 2004). 
The latest guidelines limit chemoprophylaxis to a period of 
14 days after surgery, and they also suggest intermittent pneu-
matic compression (IPC) without any administration of antico-
agulants as one choice for postoperative prophylaxis because 
of its preventative effects (Sugano et al. 2009, Husted et al. 
2010). Thus, there is a controversy among Japanese surgeons 
about what kind of thromboprophylaxis should be employed 
after major orthopedic surgery. Also in western countries, 
some authors have questioned whether routine chemoprophy-
laxis is necessary (Callaghan et al. 2005, Dorr et al. 2007). 
Thus, a useful screening method to determine which patients 
are at high risk of postoperative VTE should be of value.
Previously, tests for global screening of the coagulation 
system were considered to be unhelpful in the diagnosis of 
thrombotic events. However, recent biochemical studies of the 
coagulation and fibrinolysis systems have led to the availability Acta Orthopaedica 2012; 83 (1): 14–21  15
of specific and sensitive tests that can detect thrombosis. At the 
same time, many different markers have been found to show 
increased expression in clinical disorders in which there is an 
imbalance between coagulation and fibrinolysis. We exam-
ined acute postoperative changes in (1) soluble fibrin (SF), 
a complex of fibrin monomer and fibrinogen derivatives; (2) 
thrombin-antithrombin complex (TAT), a marker of thrombin 
generation; (3) D-dimer, a proteolytic fragment resulting from 
degradation of a fibrin clot; and (4) plasminogen-activator 
inhibitor 1 (PAI-1), which is the main regulator of the fibrino-
lysis system. In addition, we evaluated the usefulness of assay-
ing these markers as predictors of early VTE following THA.
Patients and methods
170 patients with a mean age of 63 (38–85) years who were 
scheduled for THA between 2007 and 2010 were included. 
Patients were excluded if they had any of the following condi-
tions: (1) a prior THA requiring revision; (2) a previous his-
tory of VTE; (3) a pre-existing malignant tumor; or (4) renal 
failure (estimated glomerular filtration rate < 50 mL·min-
1·1.73 m-2). Before surgery, all patients were provided with a 
detailed explanation of the risks and alternatives to participa-
tion in the study, and all provided written informed consent. 
The study was approved by the Institutional Review Board 
of Yokohama City University (approval no., 01-10-2007-058). 
Prophylaxis for VTE
There were 2 patient groups: the IPC group (67 patients who 
underwent primary THA between 2007 and 2008) and the 
fondaparinux (FPX) group (103 patients who underwent THA 
between 2008 and 2010). At our institution, FPX has been 
used routinely since September 2008. IPC was performed on 
all patients in both groups during surgery (under anesthesia), 
and the patients were given unfractionated heparin (UFH) 
intravenously in a single dose of 20 IU/kg of body weight 
(Sharrock et al. 1999). IPC was maintained postoperatively. 
Patients usually started walking 1–2 days after surgery. The 
patients in the FPX group were also given 2.5 mg of FPX sub-
cutaneously every day for 14 days, starting on postoperative 
day 1.
Perioperative management
All patients were operated under general anesthesia. THA 
using a computed tomography-based navigation system 
was performed through a minimally-invasive anterolateral 
approach with the patient in the lateral decubitus position. 
During surgery, all patients received up to 1,500 mL of Ring-
er’s solution or hydroxyethyl starch. Fluid management after 
surgery until the next morning was routinely done with 1,000 
mL of Ringer’s solution and 500 mL of maintenance fluid.
Postoperative mobilization followed a protocol supervised 
by experienced orthopedic physiotherapists. The patients were 
allowed discharge on postoperative day 14, the day this mobi-
lization protocol was completed.
Diagnostic methods for VTE
Duplex ultrasonography (US) was performed on all patients 28 
days before surgery in order to detect any evidence of previous 
DVT of the lower limb. Absent or incomplete compressibility 
of the vein was the diagnostic criterion. For the determina-
tion of postoperative VTE, an angiography of the pulmonary 
artery and deep veins on the pelvis and the lower limbs was 
performed on all patients on postoperative day 7, by 64-slice 
multidetector row computed tomography (MDCT) using 
a nonionic contrast agent. The diagnostic criterion for VTE 
was the presence of a defect of intraluminal filling because of 
thrombosis in the pulmonary artery or deep vein. When the 
presence of VTE was suspected by MDCT, a duplex US was 
also employed in order to confirm the presence of DVT.
Following detection of the postoperative VTE, patients with 
VTE were administered UFH intravenously in order to main-
tain the activated partial thromboplastin time at 1.5–2.5 times 
that of the control value. Warfarin was administered at the 
same time, and the international normalized ratio was main-
tained at 2.0–2.5.
Blood samples
Blood samples were obtained from peripheral veins under 
short fasting conditions early in the morning, on the preopera-
tive day and on postoperative days 1, 3, 7, and 14. Plasma SF 
levels were measured using a latex photometric immunoassay 
(IATRO SF II; Mitsubishi Chemical Medience Corporation, 
Tokyo, Japan) with IF-43 monoclonal antibody raised against 
a urea-solubilized fibrin monomer. The normal upper limit for 
SF was < 7 µg/mL. PAI-1 was measured using a latex photo-
metric immunoassay (LPIA-tPAI Test; Mitsubishi Chemical 
Medience Corporation) using a reference range of 10–50 ng/
mL. Furthermore, preoperative levels of lipids such as triglyc-
erides and total cholesterol were measured, and their associa-
tion with PAI-1 was determined. Plasma D-dimer levels were 
also assayed with a latex photometric immunoassay (LPIA-
ACE D-dimer; Mitsubishi Chemical Medience Corporation). 
The normal limit was < 0.7 µg/mL. TAT was measured by 
enzyme-linked immunosorbent assay (ELISA) with a refer-
ence range of 0.1–5.0 ng/mL (Enzygnost TATmicro; Siemens 
Healthcare Diagnostics Inc., Tokyo, Japan). 
Statistics
Statistical analyses were performed using SPSS II software. 
According to a Kolmogorov-Smirnov analysis, the coagula-
tion and fibrinolysis variables showed a skewed distribution. 
Thus, these variables are presented as medians. The medians 
and interquartile ranges are plotted in the figures as a box-
and-whisker plot. In the figures, the vertical bars (whiskers) 
represent the 5th and 95th percentiles and the horizontal bars 
in the boxes represent the medians. In addition, differences in 16  Acta Orthopaedica 2012; 83 (1): 14–21
the variables between patients with VTE and those without 
were examined statistically using Student’s t-test or a two-
tailed Mann-Whitney U-test. Furthermore, the chi-square test 
and Fisher’s exact probabilities were used for the comparison 
between the observed and expected frequencies. The useful-
ness of the markers for the diagnosis of VTE was assessed by 
a receiver operating characteristic curve analysis. Values of p 
< 0.05 were considered statistically significant.
Results
In the IPC group, postoperative VTE was detected in 17 of the 
67 patients (25%), and the incidences of pulmonary embolism 
(PE) only, deep vein thrombosis (DVT) only, and both PE and 
DVT were 3, 12, and 2, respectively. In the FPX group, VTE 
was detected in 8 of the 103 patients (7%), and the incidences 
of PE only, DVT only, and both PE and DVT were 3, 5, and 0, 
respectively. The difference in the frequency of occurrence of 
VTE between the IPC and FPX groups was statistically signif-
icant (p < 0.01). All DVT occurred in the calf vein, and there 
were no cases of symptomatic DVT or PE. The distributions 
of age, sex, body mass index (BMI), duration of surgery, blood 
loss, and previous illness were similar in patients with and 
without VTE, and between the IPC and FPX groups (Table).
In the IPC group, plasma SF levels on postoperative day 1 in 
patients with VTE were higher than those in patients without 
VTE (p < 0.01) (Figure 1), and the median values were 38 
µg/mL and 10 µg/mL, respectively. Plasma SF levels rapidly 
decreased to reference range by postoperative day 3. On the 
other hand, in the FPX group SF levels were similar in patients 
with and without VTE (Figure 2).
In the IPC group, plasma PAI-1 levels on postoperative day 
1 in patients with VTE were higher than those in patients with-
out VTE (p < 0.01) (Figure 1). The median PAI-1 values on 
postoperative day 1 were 93 ng/mL for patients with VTE and 
40 ng/mL for patients without VTE. In addition, in both the 
IPC and FPX groups plasma D-dimer levels showed bimodal 
peaks that were evident on postoperative days 1 and 7. In 
the IPC group, significant differences in the plasma D-dimer 
levels were not seen on postoperative day 1, but they were 
seen on postoperative day 7 (p < 0.01). The median D-dimer 
values on day 7 were 21 µg/mL for patients with VTE and 10 
µg/mL for patients without VTE (Figures 1 and 2).
IPC patients with VTE also showed higher levels of TAT on 
postoperative day 1 (p < 0.05); the median values were 24 µg/
mL for patients with VTE and 14 µg/mL for patients without 
VTE. On the other hand, statistically significant differences in 
TAT levels were not found in patients of the FPX group.
To evaluate the usefulness of the markers SF, PAI-1, and 
TAT that were detected in the IPC group on postoperative 
day 1, their cutoff levels with sensitivities and specificities 
were determined by receiver operating characteristic (ROC) 
analysis (Figure 3). The cutoff level of SF was determined to 
be 19.8 µg/mL, with a sensitivity of 88% and a specificity of 
62%. The cutoff level of PAI-1 was 53.5 ng/mL, with a sen-
sitivity of 78% and a specificity of 72%, and that of TAT was 
found to be 18.1 ng/mL with a sensitivity of 85% and a speci-
ficity of 66%. Next, using a multivariate logistic regression 
analysis, we found that SF and PAI-1 levels on postoperative 
day 1 had statistically the strongest association with throm-
botic tendency. Furthermore, comparison of the area under the 
ROC curves showed that the measurements of SF and PAI-1 
on postoperative day 1 had the best performance with respect 
Patient characteristics
 
  IPC group  FPX group 
  Patients  Patients  Patients Patients
  with VTE  without VTE  with VTE  without VTE
Characteristics  n = 17  n = 50  n = 6  n = 97  p-value
Age, years a    68 (8)    62 (12)    58 (8)    61 (12)  0.1
Gender: male/female, n      3/14    17/33      6/0    21/76  0.5
Weight, kg a    58 (14)    58 (13)    59 (14)    58 (13)  0.9
Body mass index a    24 (6)    23 (5)    24 (5)    24 (5)  0.9
Primary hip disease, n          0.8
  Osteoarthritis    15    36      4    79 
  Rheumatoid arthritis      0      3      0      7 
  ANFH      2      6      2    11 
  PVNS      0      1      0      0 
Preoperative plasma levels of: 
  Triglycerides, mg/dL a    92 (35)  108 (40)    99 (32)    98 (41)  0.7
  Total cholesterol, mg/dL a  228 (44)  199 (31)  202 (26)  222 (36)  0.7
Operation length, min a  182 (62)  162 (36)  153 (39)  161 (37)  0.2
Blood loss, mL a  557 (193)  547 (217)  525 (137)  624 (265)  0.4
a Values are mean (SD).
IPC: intermittent pneumatic compression; FPX: fondaparinux sodium; VTE: venous thromboembolism; 
OA: osteoarthritis; RA: rheumatoid arthritis; ANFH: avascular necrosis of femoral head; 
PVNS: pigmented villonodular synovitis.Acta Orthopaedica 2012; 83 (1): 14–21  17
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Figure 1. Changes in coagulation markers in 
patients who underwent intermittent pneumatic 
compression only. Plasma levels of soluble fibrin 
(SF), plasminogen activator inhibitor type 1 (PAI-
1), D-dimer, and thrombin-antithrombin complex 
(TAT) in patients who underwent intermittent 
pneumatic compression alone were measured 
preoperatively and on postoperative days 1 
(PO1D), 3 (PO3D), 7 (PO7D), and 14 (PO14D). 
The boxes represent the interquartile ranges. The 
perpendicular lines (whiskers) represent the fifth 
and ninety-fifth percentiles and the horizontal bars 
in the boxes indicate the median values. On the 
day after surgery, the plasma levels of SF, PAI-1, 
and TAT were found to be increased in the venous 
thromboembolism (VTE) group compared to the 
non-VTE group. The changes in the D-dimer levels 
showed bimodal peaks on postoperative days 1 
and 7 in both groups. Statistically significant differ-
ences were observed in the D-dimer levels mea-
sured on postoperative day 7. a p < 0.05 and b p 
< 0.01. 
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Figure 2. Changes in coagulation markers in 
patients who received subcutaneous injections 
of fondaparinux sodium. Plasma levels of soluble 
fibrin (SF), plasminogen activator inhibitor type 1 
(PAI-1), D-dimer, and thrombin-antithrombin com-
plex (TAT) in patients who received subcutaneous 
injections of fondaparinux sodium were mea-
sured preoperatively and on postoperative days 1 
(PO1D), 3 (PO3D), 7 (PO7D), and 14 (PO14D). 
The boxes represent the interquartile ranges. 
The perpendicular lines represent the fifth and 
ninety-fifth percentiles and the horizontal bars in 
the boxes indicate the median values. The levels 
of SF, PAI-1, D-dimer, and TAT were similar in the 
patients in the fondaparinux group who had or did 
not have VTE.18  Acta Orthopaedica 2012; 83 (1): 14–21
Figure 3. Receiver operating characteristic (ROC) curve analysis of the accuracy of the 
quantitative soluble fibrin (SF), plasminogen activator inhibitor type 1 (PAI-1), and throm-
bin-antithrombin complex (TAT) levels on postoperative day 1 and D-dimer levels on day 7. 
The area under the ROC curve (AUC) is given in each diagram with the 95% confidence 
interval in parentheses. 
Figure 4. Discrimination of postoperative venous thromboembolism (VTE) using levels of soluble fibrin (SF) and plasminogen activator inhibitor 
type 1 (PAI-1). Increases in either SF or PAI-1 on postoperative day 1 above their cut-off levels provided 100% sensitivity and 67% specificity 
in predicting VTE when patients were not given fondaparinux sodium postoperatively (left panel). In addition, when this criterion was applied to 
patients who received subcutaneous injections of fondaparinux following surgery, 7 of the 8 patients with VTE met the criterion and a 98% (48/49) 
negative agreement rate was found (right panel).
to their discrimination ability (Figure 3). 
Also, there was no statistically significant 
correlation between the levels of PAI-1 and 
the levels of other coagulation markers.
Figure 4 shows scatter graphs of SF and 
PAI-1 levels, with 2 lines at each cutoff 
level. These lines divide the patients into 2 
groups: those with higher marker levels and 
those with lower levels, and these divisions 
provided a sensitivity of 100%, a specificity 
of 67%, and a positive predictive value of 
50%. In addition, when this criterion was 
applied to patients in the FPX group, 7 of 
the 8 with VTE met the criterion and there 
was a negative agreement rate of 98.0% 
(48/49).
Discussion
VTE is a common complication after total 
hip or knee arthroplasty, but most VTE is 
generally asymptomatic. Due to the lack 
of symptoms, the condition goes mostly 
unnoticed and the patient is therefore left 
untreated. However, approximately 10–20% 
of crural thrombi, most of which are asymp-
tomatic DVT, move to the proximal veins 
(Labropoulos et al. 2002). Proximal propa-
gation of a thrombus can lead to free-floating Acta Orthopaedica 2012; 83 (1): 14–21  19
status, resulting in critical complications after being released 
as a massive embolus (Baldridge et al. 1990). According to 
the PREVENT study (Ridker et al. 2003), the recurrence rate 
of VTE is approximately 7%, and long-term, low-intensity 
warfarin therapy reduces this risk by more than half. Thus, 
we suggest that all cases of VTE—including asymptomatic 
VTE—should be detected and treated with anticoagulants, 
and that an early and simple modality for screening of VTE 
should be established.
Highly invasive surgery has been shown to commonly result 
in a hypercoagulable state and increasing plasma levels of SF 
and TAT during the initial postoperative stage (Brueckner et 
al. 2003, Sudo et al. 2009). This is consistent with our pres-
ent findings that plasma SF and TAT levels were elevated on 
postoperative day 1. Also, considering the substantial eleva-
tion of these markers in patients who developed VTE in the 
IPC group, we suggest that the onset of VTE is associated with 
a hypercoagulable state in the early phase after THA. 
A high level of SF in clinical plasma samples has been rec-
ognized to be an indicator of ongoing intravascular coagula-
tion processes (Hamano et al. 2005). SF expresses an acute 
intravascular fibrin formation as well because SF is one of 
circulating materials growing fibrin clots. Regarding the use-
fulness of SF for possible diagnosis of VTE, it was previously 
suggested that SF levels on the day after total hip or knee 
arthroplasty may be valuable for prediction of postoperative 
VTE (Sudo et al. 2009, Niimi et al. 2010).
Similarly to SF, TAT is considered to be associated with 
VTE following THA (Sudo et al. 2009). Formation of TAT is, 
however, only an indirect measure of an activated coagulation 
system (Brueckner et al. 2003), and its measurement is often 
influenced by the peripheral blood sampling techniques used 
under venous occlusion. Sensitivity and specificity of TAT 
measurement on the day after THA have been reported to be 
73% and 27%, respectively (Cofrancesco et al. 1998). Thus, 
TAT has been found to be inferior to other markers as a predic-
tor of VTE (Brueckner et al. 2003, Hamano et al. 2005).
PAI-1 is the principal inhibitor and critical regulator of plas-
minogen activator. Several clinical studies have found that 
plasma PAI-1 levels may be affected by lipid levels or vas-
cular endothelial cell injury, and these factors may therefore 
increase the risk of thrombosis or embolism (Hamsten et al. 
1987, Juhan-Vague et al. 1987). Furthermore, PAI-1 is pro-
duced at the site of inflammation following tissue injury. It 
has been reported that plasma PAI-1 levels are associated with 
surgical invasion, and that the increased levels of the fibrino-
lytic inhibitor that result from this may therefore be a major 
contributor to fibrinolytic shutdown (Kassis et al. 1992). In the 
present study, plasma PAI-1 levels were substantially elevated 
in IPC patients with VTE, despite the absence of any signifi-
cant differences in other thrombotic risk factors such as lipid 
levels, BMI, or pre-existing diseases. Thus, we believe that 
changes in the fibrinolytic system may also be associated with 
the development of VTE.
Plasma D-dimer levels increase after the cleavage of formed 
thrombi by activated plasmin, and they have been suggested 
to be a useful marker for the diagnosis of VTE. The sensi-
tivity and specificity for proximal DVT were 79% and 36%, 
respectively. In the present study, D-dimer measurements on 
postoperative day 7 were different in patients with and without 
VTE in the IPC group. However, at this stage, VTE is already 
evident, and we therefore suggest that D-dimer is not useful as 
an early predictor of this disorder.
An imbalance between coagulation and fibrinolysis contrib-
utes to excessive fibrin deposition in the vascular wall because 
both systems are composed of a complex cascade of mole-
cules and closely influence each other (Aso 2007). Our results 
indicate that this imbalance can be detected with a combined 
assay involving SF as a coagulation marker and PAI-1 as a 
fibrinolytic marker. As shown in Figure 4, some of the patients 
with VTE had high levels of SF but low PAI-1 levels, whereas 
some had low SF levels and high PAI-1 levels. These data sug-
gest that the onset of VTE after THA may be due to a hyper-
coagulable state, a highly regulated fibrinolytic state, or both.
We think that the combined measurement of SF and PAI-1 
on postoperative day 1 is a useful screening method for 
patients who are at high risk of developing postoperative VTE. 
Our findings suggest that plasma levels of SF and PAI-1 on 
postoperative day 1 have the potential to provide an alterna-
tive chemoprophylaxis regimen for VTE after THA. However, 
the high sensitivity of this screening for prediction of VTE 
on day 7 was observed in patients receiving perioperative 
heparin and short-term IPC. It is necessary to investigate this 
further using different thromboprophylaxis methods and vari-
ous imaging modalities. In addition, investigation of late VTE, 
which occurs 2–3 months after surgery, should be performed 
to confirm whether chemoprophylaxis is necessary for low-
risk patients.
The levels of SF, PAI-1, TAT, and D-dimer in patients in the 
FPX group were similar between patients with and without 
VTE. This is because the use of FPX regulated the hyperco-
agulable state and the formation of thrombi, even in patients 
whose levels of coagulation markers were high in the early 
phase of surgery. Also, the reason why there were no differ-
ences in the levels of D-dimer between patients with and with-
out VTE may be that FPX functioned as a treatment agent for 
already-developed VTE. 
In both the IPC and FPX groups, VTE may have developed 
in some cases before the first measurements. Thus, delayed 
screening for VTE—i.e. on the day after the surgery—was 
not helpful, and screening should ideally be performed during 
or immediately after the surgery. Only 1 Japanese study has 
examined SF levels in the perioperative period following 
THA, and was unable to demonstrate the usefulness of these 
markers during or immediately after surgery because of a vari-
ety of factors. Although our measurements were delayed, our 
method is one of the fastest for screening of patients who are 
at high risk of developing VTE.20  Acta Orthopaedica 2012; 83 (1): 14–21
A 64-slice MDCT was employed as the imaging modality 
for the detection of postoperative VTE in this study, because 
with this technique one can simultaneously perform both pul-
monary angiography and venography of the lower extremi-
ties. In addition, it is a less invasive technique than conven-
tional ascending venography, requires considerably less time 
(approximately 5–8 min), and is technically simple (Lim et al. 
2004). However, MDCT has several disadvantages, such as 
exposure of the patient to radiation, beam-hardening artifacts 
around the arthroplastic joint materials, and contrast-induced 
nephropathy. Concerning the accuracy of DVT detection since 
the advent of MDCT, several studies have shown that the diag-
nostic ability of indirect CT venography is comparable to US 
(Duwe et al. 2000, Loud et al. 2001, Lim et al. 2004), and 
both the sensitivity and the specificity in these studies ranged 
from 89–100%. US has recently become a widely accepted 
primary modality in the diagnosis of DVT because of its 
advantages, including high accuracy, painlessness, noninva-
siveness, and reduced cost. Furthermore, US does not require 
radiation or contrast materials and there are no side effects. 
Thus, we employed duplex US for the preoperative screening 
of DVT and for postoperative confirmation of DVT suspected 
by MDCT.
In addition to imaging modalities, other factors may have 
affected the incidence of postoperative VTE, such as the 
method of anesthesia, duration of surgery, perioperative injec-
tion of heparin, immobilization, and duration of hospital stay 
(Husted et al. 2010, Brueckner et al. 2003). To minimize the 
influence of these factors on the occurrence of VTE, mobiliza-
tion and rehabilitation directed by a physiotherapist were initi-
ated within 24 hours of surgery. All patients underwent phys-
iotherapy, and mobilization was frequently encouraged in free 
time during the hospital stay. Because of the limitation that the 
FPX injection can only be administered by nurses or doctors 
during the hospital stay and cannot be self-administered by 
patients at home, in Japan the duration of the hospital stay is 
longer than in other countries. The postoperative hypercoagu-
lation state may change if epidural anesthesia is used (Brueck-
ner et al. 2003) or if the duration of surgery is shortened. In 
the present study, a computed tomography-based navigation 
system was used to insert the joint implant accurately in all 
the patients. This system generally takes time to set and reg-
ister. Furthermore, MIS techniques were used for all cases. It 
is possible that prolonged surgery may have resulted in the 
hypercoagulable state. Perioperative administration of hepa-
rin may also affect the incidence of postoperative VTE or the 
postoperative coagulation state, although the dose of heparin 
was considerably low.
In conclusion, patients undergoing primary THA are at a 
high risk of developing VTE, which is possibly induced by a 
hypercoagulable or regulated fibrinolytic state during the early 
postoperative phase. Plasma levels of SF and PAI-1 on day 1 
after THA may be of value in providing an indication of the 
balance between coagulation and fibrinolysis, and in predict-
ing VTE following THA. When high levels of SF or PAI-1 
are observed on the day after surgery, there is a higher risk of 
postoperative VTE.
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